Fresh Tracks Therapeutics (FRTX) S-3 Shelf registration

Exhibit 12.1

STATEMENT OF COMPUTATION OF RATIOS

	Three Months Ended March 31, 2012		Year Ended December 31,
			2011			2010			2009			2008			2007
Fixed charges:
Interest expense	$	—	$	—		$	—		$	2,000		$	21,000		$	96,000
Estimated interest portion of rent expense		341,000		1,460,000			1,599,000			1,731,000			1,859,000			1,967,000
Total fixed charges	$	341,000	$	1,460,000		$	1,599,000		$	1,733,000		$	1,880,000		$	2,063,000
Earnings:
Net income (Loss) from continuing operations before income taxes	$	244,000	$	(7,283,000	)	$	(30,385,000	)	$	(28,558,000	)	$	(36,896,000	)	$	(35,894,000	)
Add: Fixed charges		341,000		1,460,000			1,599,000			1,733,000			1,880,000			2,063,000
Amortization of capitalized interest		—		—			—			—			—			—
Total earnings	$	585,000	$	(5,823,000	)	$	(28,786,000	)	$	(26,825,000	)	$	(35,016,000	)	$	(33,831,000	)
Ratio of earnings to fixed charges		1.7x		—			—			—			—			—
Ratio of earnings to combined fixed charges and preference dividends(1)		1.7x		—			—			—			—			—

(1) For the years ended December 31, 2011, 2010, 2008, 2007 and 2006, the earnings were insufficient to cover fixed charges by $7,283,000, $30,385,000, $28,558,000, $36,896,000 and $35,894,000, respectively.